Cancer Vaccines: Recent Insights and Future Directions

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Cancer immunotherapy has advanced significantly, with mRNA vaccines showing efficacy against tumor-specific antigens (TSAs).
• Neoantigens offer personalized therapy but face challenges with scarce immunogenic neoepitopes.
• Tumor-associated antigens (TAAs), such as human endogenous retroviruses (HERVs), are emerging as promising alternatives due to high tumoral expression and immunogenicity.

Purpose of the Study:

• To review the status and limitations of TSA-directed mRNA cancer vaccines.
• To derive lessons from TSA vaccines and checkpoint inhibitors for TAA vaccine development.
• To explore strategies for enhancing TAA vaccine efficacy, particularly for tumors lacking pre-existing immune structures.

Main Methods:

• Literature review and analysis of current research on mRNA cancer vaccines.
• Evaluation of clinical outcomes and challenges associated with TSA-based immunotherapies.
• Assessment of HERVs and other TAAs as potential targets for novel cancer vaccines.

Main Results:

• mRNA vaccines targeting TSAs have demonstrated clinical success but face limitations.
• TAAs, including HERVs, present viable alternatives with potential for broad T cell and B cell responses.
• Checkpoint inhibitors are effective in highly mutated tumors with tertiary lymphoid structures.

Conclusions:

• Shared antigen presentation (B cell, CD4+, CD8+ T cells) is crucial for sustained T cell expansion and efficacy in tumors lacking tertiary lymphoid structures.
• TAA-based vaccines could broaden the efficacy of current immunotherapies to more tumor types and stages.
• Integrating insights from TSA vaccines and checkpoint inhibitors will guide future TAA vaccine development for improved cancer treatment.